Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Precancerous Conditions 1Colonic Neoplasms 1

Interventions

Biopsy 12Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9fludarabine phosphate 8Whole-Body Irradiation 8Polymerase Chain Reaction 7Tacrolimus 6Mycophenolic Acid 6Gene Expression Profiling 6Colposcopy 6Busulfan 6Microarray Analysis 5Immunohistochemistry 5Epoetin Alfa 5Celecoxib 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Vaginal Smears 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Comparative Genomic Hybridization 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precancerous Conditions × Atorvastatin × Other neoplasm × Clear all
NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
85 enrolled 10 charts
GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡